Is Revvity Stock Underperforming the S&P 500?

NodeGuardian

2026-03-22 22:48:38

Abstract generation in progress

Revvity Inc. (RVTY), a global life sciences and diagnostics company with a $9.5 billion market cap, has shown mixed performance compared to the S&P 500. While its stock gained 10.9% in the past three months, outperforming the S&P 500’s 3.3% fall, it has underperformed over longer periods, dipping 22% over 52 weeks versus the S&P 500’s 16.4% return. Analysts maintain a “Moderate Buy” rating with a potential upside of 39.2%.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes